In this episode, Sacha Hebbert sits with the CEO, Benjamin Lightburn of Filament Health, to discuss the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.
In this episode of the Psychedelic Spotlight podcast, Global Trac Solutions, Inc. CEO, David Flores, sits down with Payton Nyquvest, CEO and Chairman of Numinus Wellness, Inc.
During our time at Wonderland Miami, $PSYC CEO, David Flores,…
Mydecine Innovations Group’s Director, CEO & Co-Founder, Joshua Bartch chats with our Director of Content, Jill Ettinger.
Top 10 Psychedelic stocks to own according to PSIL ETF (DO I AGREE?)
What’s up Psychedelic Investors!?! Today we are looking at the actively managed Psychedelic Medicines ETF, PSIL, run by Advisor Shares.
Before we get into that though, make sure you go check out psychedelicspotlight.com and sign up for their weekly newsletter. I am featured in each one, with a 3:30 clip summarizing the biggest events in the psychedelic medicines world over the past week. It is essential!
On today’s episode we go through each of the top ten holding in PSIL, including MindMed (MNMD /MMED), Compass Pathways (CMPS), atai Life Sciences (atai), Cybin (CYBN), Field Trip (FTRP), Numinus, (NUMI) and more.
For some of the lesser known companies, such as Seelos Therapeutics, Wesana Health and GreenBrook TMS, we give a brief rundown of the company.
Investing in an actively managed psychedelic stocks ETF can be a great opportunity for those who believe in the ability of psychedelics to heal mental health issues such as PTSD and depression, but are not sure which companies are best to invest in. PSIL is actively managed, which means that their team of experts are picking what they believe to be the best stocks in the industry.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PSIL #ThePsychedelicInvestor
In this episode, Dr. Khamsehzadeh delves into our historical and ancestral relationship to psilocybin and theorizes how mushrooms have impacted the development of the brain.
Project Solace uses real-world data to inform development of regulated psilocybin therapy, led by Canadian non-profit TheraPsil
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
